Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing Co.'s proprietary topical drug candidates for dermatological therapy. Co.'s main product candidate, FMX101 (4% minocycline foam), is being developed for the treatment of moderate-to-severe acne and its second product candidate, FMX103 (1.5% minocycline foam), is being developed for the treatment of moderate-to-severe papulopustular rosacea. Both product candidates are topical foam formulations of the antibiotic minocycline and were developed using its Molecule Stabilizing Technology, a proprietary foam platform designed to optimize the topical delivery of minocycline.
|
Free FOMX Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Strong Buy (4.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |